JPMorgan Upgrades CytomX Therapeutics (CTMX) to Neutral, 'Entering a Catalyst Rich Period'
Tweet Send to a Friend
(Updated - April 22, 2024 4:39 AM EDT)
JPMorgan analyst Anupam Rama upgraded CytomX Therapeutics (NASDAQ: CTMX) from Underweight ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
JPMorgan analyst Anupam Rama upgraded CytomX Therapeutics (NASDAQ: CTMX) from Underweight ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
